Factors affecting sustained medication adherence and its impact on healthcare utilization in patients with diabetes

Journal of Pharmaceutical Health Services Research

Volumn 4, Issue 2, 2013, Pages 89-94

  Juarez, Deborah Taira ^a   Tan, Candace ^a   Davis, James ^b   Mau, Marjorie ^b  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

^b UNIVERSITY OF HAWAII   (United States)

Author keywords

Health disparities; Healthcare utilization; Medication adherence

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; EMERGENCY WARD; ETHNICITY; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RACE DIFFERENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE;

EID: 84876846631     PISSN: 17598885     EISSN: 17598893     Source Type: Journal    
DOI: 10.1111/jphs.12016     Document Type: Article

References (24)

1. Ostenberg L. Adherence to medications. N Engl J Med 2005; 353: 487-497.
2. Lawrence DB etal. Relationship of oral antihyperglycemic (sulfonylurea or metformin) medication adherence and hemoglobin A1c goal attainment for HMO patients enrolled in a diabetes disease management program. J Manag Care Pharm 2006; 12: 466-471.
3. Ho PM etal. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes. Arch Intern Med 2006; 166: 1836-1841.
4. Rhee MK etal. Patient adherence improves glycemic control. Diabetes Educ 2005; 31: 240-250.
5. Nair KV etal. Prescription co-pay reduction program for diabetic employees. Popul Health Manage 2010; 13: 235-245.
6. Rozenfeld Y etal. Oral antidiabetic medication adherence and glycemic control in managed care. Am J Manag Care 2008; 14: 71-75.
7. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract 2011; 65: 314-322.
8. Gellad WF etal. A Review of Barriers to Medication Adherence: a Framework for Driving Policy Options. Technical report, document no: TR-765-MVC [online]. Santa Monica, CA: The Rand Corporation, 2009. http://www.rand.org/pubs/technical_reports/TR765.html (accessed 10 October 2012).
9. Bloomgarden Z. Five Ms of medication adherence. J Diabetes 2011; 3: 169-171.
10. Briesacher BA etal. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28: 437-443.
11. Emslie-Simith A etal. The problem of polypharmacy in type 2 diabetes. Br J Diabetes Vasc Dis 2003; 3: 54-56.
12. van Bruggen R etal. Refill adherence and polypharmacy among patients with Type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf 2009; 18: 983-991.
13. Clark DO etal. A chronic disease score with empirically derived weights. Med Care 1995; 33: 783-795.
14. State of Hawaii Department of Health. Hawaii Behavioral Risk Factor Surveillance System [online]. Honolulu, HI: Department of Health, 2011. http://hawaii.gov/health/statistics/brfss/index.html (accessed 10 Sept 2012).
15. Choudhry NK etal. Measuring concurrent adherence to multiple related medications. Am J Manag Care 2009; 15: 457-464.
16. Martin BC etal. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 2009; 43: 36-44.
17. StataCorp. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP, 2009.
18. World Health Organization. Adherence to Therapies: Evidence for Action. Geneva: World Health Organization, 2003.
19. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: Institute of Medicine, 2009.
20. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 2009; 8: 453-463.
21. Baigent C etal. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
22. Law MR etal. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665.
23. Glader EL etal. Persistent use of secondary preventive drugs declines rapidly during the first 2 years after stroke. Stroke 2010; 41: 397-401.
24. Haynes RB etal. Interventions for enhancing medication adherence. Cochrane Database Syst Rev 2008; (2): CD000011.